NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
4.870
-0.030 (-0.61%)
At close: Aug 5, 2025, 4:00 PM
4.715
-0.155 (-3.18%)
After-hours: Aug 5, 2025, 4:00 PM EDT
New Relic Revenue
NeOnc Technologies Holdings had revenue of $39.99K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $79.99K, up 13.52% year-over-year. In the year 2024, NeOnc Technologies Holdings had annual revenue of $83.00K with 17.79% growth.
Revenue (ttm)
$79.99K
Revenue Growth
+13.52%
P/S Ratio
1,120.34
Revenue / Employee
$9,999
Employees
8
Market Cap
92.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
Dec 31, 2022 | 20.00K | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNTHI News
- 1 day ago - NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer - GlobeNewsWire
- 6 days ago - NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors - GlobeNewsWire
- 13 days ago - CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc. - GlobeNewsWire
- 4 weeks ago - NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform - GlobeNewsWire
- 2 months ago - NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs - GlobeNewsWire
- 4 months ago - NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets - GlobeNewsWire
- 4 months ago - NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September - GlobeNewsWire
- 4 months ago - NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President - GlobeNewsWire